Projected clinical benefits of dapagliflozin in patients with heart failure with preserved ejection fraction supplementary dataset

Aims: To address the projected clinical benefits of dapagliflozin among patients with heart failure (HF)

with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). Methods: A

multicenter, prospective, cohort study of patients ≥50 years admitted with HF to Spanish internalmedicine

departments. The projected clinical benefits of dapagliflozin were calculated from the DELIVER trial.

Results: A total of 4049 patients were included; 3271 (80.8%) were eligible for dapagliflozin treatment,

according to DELIVER criteria. Within 1 year after discharge, 22.2% were rehospitalized for HF and

21.6% died. Implementation of dapagliflozin would translate into an absolute risk reduction of 1.3% for

mortality and 5.1% for HF readmission. Conclusion: HF patients with preserved or mildly reduced ejection

fraction have a high risk of events. The use of dapagliflozin could substantially reduce the HF burden.